BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Completion of Corporate Actions, Engagement of North Equities Corp for Digital Marketing Expertise

October 20, 2022 08:50:00

MetAlert (OTC: MLRT), a pioneer in the field of health and safety, wearable GPS human and asset tracking systems, today announced its receipt of final approval from the regulatory bodies and completion of all corporate actions filed in the 14c on July 19. Formerly known as GTX Corp, MetAlert Inc. is now operating and trading under its new ticker symbol MLRT. In addition, as part of its marketing strategy, MetAlert retained North Equities Corp to provide digital marketing services aimed at building awareness of its rebranding and positioning in the medical device, telehealth and remote patient monitoring (“RPM”) industry. “We believe that North Equities brings unique skills and expertise that will help strengthen our existing team, as we continue to grow and build recognition in the marketplace,” said MetAlert CEO Patrick Bertagna. “We are excited about the possibilities that lie ahead and with our team’s expertise in digital marketing and keen focus on strategic brand building, we look forward to achieving great things in the future as we navigate the ever-changing markets of today.”

To view the full press release, visit

About MetAlert Inc.

MetAlert, a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, is supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. The company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technology, MetAlert products enable subscribers to track in real time the whereabouts of people or high-value assets. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable, technology-tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism or traumatic brain injury. MetAlert’s business model is built around technology innovation and holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in more than 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about the company, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork